Press Releases

Press Releases

  • May 19, 2022
    Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
  • May 17, 2022
    Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference
  • May 13, 2022
    Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
  • May 10, 2022
    Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting
  • May 5, 2022
    Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
  • April 21, 2022
    Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations
  • March 28, 2022
    Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
  • March 22, 2022
    Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference
  • January 5, 2022
    Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones
  • January 4, 2022
    Aileron Therapeutics to Present at Upcoming Investor Conferences